Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049590 | 0.81 | MIF (0.48) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL10615043 | 0.79 | TDP1 (0.54) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL27873 | 0.79 | TDP1 (0.54) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL8069515 | 0.78 | ENPP2 (0.50) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL27621561 | 0.77 | TDP1 (0.52) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL55943 | 0.75 | TSHR (0.50) | ENPP2KDM4EMGLLMAPK1TDP1 | |
| Ethylene SCHEMBL10425506 | 0.74 | TDP1 (0.50) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL9460699 | 0.74 | CYP3A4 (0.46) | ALDH1A1MAPK1TDP1 | |
| SCHEMBL115285 | 0.74 | NPC1 (0.46) | MAPK1TDP1 | |
| SCHEMBL30365208 | 0.73 | TDP1 (0.48) | ALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083706-A1 | BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-9234048-B2 | Boronate-mediated delivery of molecules into cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-01 | — | — | US | disclosed |
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | BCAP31, PHAX, BTD | ENPP2 2234/4885KDM4E 2806/4885ALDH1A1 4591/4885 |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | ENPP2 1003/4885KDM4E 2732/4885ALDH1A1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.